Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 3Phase 1 3Phase EARLY_PHASE1 1Phase 4 1Phase 1/2 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Muscle Invasive Bladder Urothelial Carcinoma 1

Interventions

Nivolumab 5pembrolizumab 4Temozolomide 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Rituximab 2Radiosurgery 2Paclitaxel 2Neoadjuvant Therapy 2Ipilimumab 2Gemcitabine 2Fluorodeoxyglucose F18 2Dexamethasone 2Cyclophosphamide 2Cisplatin 2Carboplatin 2Biopsy 2Bevacizumab 2venetoclax 1theanine 1temsirolimus 1tafasitamab 1sugemalimab 1senicapoc 1semaglutide 1sacituzumab govitecan 1prednylidene 1pirtobrutinib 1perampanel 1paricalcitol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × enfortumab vedotin × 30 days × Clear all
NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

Brigham and Women's Hospital

Phase EARLY_PHASE1 Enrolling by invitation
18 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡